Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Chambery – page 12

785 clinical trials in Chambery, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Chambery at a glance
785
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

785 trials in Chambery

Open in trial search

Hypertrophic cardiomyopathy

Recruiting

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Renal transplant

Recruiting

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belatacept
  • Sponsor:Centre Hospitalier Universitaire Rouen

Non-small cell lung cancer

Recruiting

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Haematological malignancy+1

Recruiting

Study on Fecal Microbiota Transplantation to Prevent Complications in Patients After Stem Cell Transplant for Blood Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:CHU Gabriel-Montpied

Renal cell carcinoma

Recruiting

Study on Digital Monitoring of Symptoms in Patients with Advanced Kidney Cancer Treated with Cabozantinib and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Centre Francois Baclesse

Neovascular age-related macular degeneration

Recruiting

Study of Faricimab Treatment Given Every 24 Weeks in Patients with Age-Related Macular Degeneration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Peripheral T-cell lymphoma unspecified+1

Recruiting

Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:LYSARC

Heart failure with reduced ejection fraction

Recruiting

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Omecamtiv mecarbil
  • Sponsor:Cytokinetics Inc.

Pancreatic carcinoma

Recruiting

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Centre Hospitalier Universitaire Rouen

Adenocarcinoma pancreas

Recruiting

Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Gercor

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Blastic plasmacytoid dendritic cell neoplasia

Recruiting

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:French Innovative Leukemia Organization

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Chambery

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel therapeutic combinations and treatment strategies.

  • Multiple Myeloma Treatments
  • Follicular Lymphoma Studies
  • Diffuse Large B-cell Lymphoma Research

Advanced trials exploring combinations of immunotherapy and targeted treatments for blood cancers.

02 Lung Cancer Research

Studies examining innovative treatments for non-small cell lung cancer, particularly focusing on immunotherapy approaches.

  • Immunotherapy Combinations
  • Elderly Patient Treatment Options
  • Novel Therapeutic Strategies

Emphasis on improving treatment outcomes through targeted and combination therapies.

03 Preventive Medicine

Research on pneumococcal vaccines and preventive treatments, including studies in specialized patient populations.

  • Vaccine Immunogenicity
  • Safety Studies
  • High-Risk Patient Groups

Focus on vaccine effectiveness during acute illness conditions.

04 Breast Cancer Studies

Clinical trials examining treatments for hormone-sensitive breast cancer, including targeted therapies and hormone treatment optimization.

  • Hormone Therapy Duration
  • Metastatic Disease Management
  • Biomarker Studies

Investigation of personalized treatment approaches based on molecular markers.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.